Clinical Trial

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Study acronym: ZENITH AD-1
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approximately 15 months.
Protocol Amendment History 1 change
notable Trial sites expanded: 1 -> 12 locations 2026-08-05
Trial Details
NCT Number NCT07690371
Lead Sponsor Nektar Therapeutics
Conditions Moderate-to-Severe Atopic Dermatitis
Enrollment 510 participants
Start Date 2026-06-29
Primary Completion 2028-05 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-04